Malaria Makes Comeback Amid Coronavirus Pandemic — Part 2 by Gospel for Asia

WILLS POINT, TX — GFA World (Gospel for Asia) founded by K.P. Yohannan, has been the model for numerous charities like GFA World Canada, to help the poor and deprived worldwide, issued this second part of a Special Report update on Malaria making a comeback amid the worldwide impact of the COVID 19 Pandemic.

Progress Ebbs and Flows in the Fight to Beat Malaria

Recent developments in the fight against Malaria have placed a heightened spotlight on World Malaria Day, observed on April 25. Fortunately, despite the high death toll and other troublesome signs lately, not all the news about malaria treatment is bad. There are gains amid the setbacks.

This woman in West Bengal was very grateful to Believers Eastern Church and its leaders for providing her with a mosquito net to protect herself and her family from vector borne diseases like malaria.

One positive example is Myanmar, where the annual malaria death toll of 3,800 a decade ago has decreased to approximately 170. The Global Fund to Fight AIDS, Tuberculosis and Malaria credits the efforts of 17,000 community volunteers who provide rapid testing and treatment, with serious cases referred to health facilities. Volunteers also educate the public through national antimalaria campaigns.14 Unfortunately, it’s unknown if the recent military coup in Myanmar will adversely impact the recent progress it’s achieved in the prevention of malaria.

News of another positive development appeared last October in Legion. About the same time the United States revealed a COVID-19 vaccine would be ready by the end of 2020, the Canadian magazine reported that a noted medical journal announced a new approach to fighting malaria.

Legion reported a clinical researcher for the U.S. National Institute of Allergy and Infectious Diseases has developed a vaccine for mosquito-borne diseases, based on mosquito spit. It causes the immune system to recognize mosquito saliva proteins and produce antibodies. The antibodies promote immunity by binding to pathogens to prevent them from damaging cells, plus coating pathogens and alerting other immune cells to attack and remove them.

“Those antibodies recognize the proteins the next time they’re encountered, sparking an immune response that goes into action to impair or prevent infection — and not just to malaria, it turns out,” wrote author Sharon Adams. “In animal studies, saliva vaccines impaired development of mosquito-borne Zika virus and sandfly-borne leishmaniasis.”15

In the first human trial of this vaccine in 2017, Adams said a strong immune response was observed among 49 volunteers, with only minor side effects. Next it will be tested on larger groups; if clinical trials continue to prove successful, the first effective malaria vaccine may be just around the corner.

Maya from a village in Uttar Pradesh was given a mosquito net as a Christmas gift by Gospel for Asia. She can now protect her family from mosquito bites that transmit vector-borne diseases like malaria, Zika, dengue, encephalitis and more.

In addition to this promising development, a European magazine carried a report from a healthcare company official saying there are antimalaria positives to be gained from the COVID-19 fight. Hogan Bassey, a Nigerian native who experienced several bouts with malaria as a child, noted that the pandemic highlighted system failings in global healthcare. He said if we are able to address those problems, the world will be better positioned to eradicate malaria and other diseases.

The chief innovation officer and founder of LivFul said his company is working with others — including nonprofits — to develop a repellent that it hopes will prove an efficient control tool. It has been working on a project in Ghana with a pharmaceutical company to improve one of the repellant’s ingredients, using LivFul’s technology to drive access.

After moving to the USA from Nigeria, Hogan Bassey began to work on an insect repellent formula to change the world. The true breakthrough for his new company, LivFul, came after partnering with a physical chemist to create a brand-new technology which allows insect repellent to remain on top of the applicant’s skin for 14 hours at a time. Photo by Terry News

“When we developed a revolutionary family-friendly insect repellent to halt the transmission of diseases like malaria and Dengue fever, we knew we could have a significant impact on insect-borne disease,” Bassey wrote in EPM Magazine. “If people in malaria-prone areas can purchase and use our repellent, these diseases can be stopped before they destroy lives, families, communities and industries.”16

Such a product won’t be the first tool developed. National Geographic recently reported hundreds of thousands of children across Kenya, Malawai and Ghana have been receiving the RTS,S vaccine, whose development has taken 35 years and cost hundreds of millions of dollars. While some African health professionals have asked if the expense and logistics of multiple vaccinations are worth it, the magazine said some Chinese scientists have been utilizing a new approach: preventing malaria from even occurring.

It goes back to 1972, when the Chinese discovered Artemisinin, a drug used to treat malaria. Now, scientists there believe Artemisinin Combination Therapies (ACTs) can be delivered to an entire community simultaneously, through Mass Drug Administrations. The goal is to reduce levels of the malaria parasite in human blood, so mosquitoes won’t contract it and spread it.

“The life cycle for a mosquito is 30 days,” explains Ethan Peng, senior manager in Kenya for the Chinese company New South, which manufactures ACTs. “So by mass medication, we can clear the source from all human beings (so) the mosquitoes cannot pick up on the malaria parasite again with their short lifespan.”17

Click here, to read more about this article.

Click here, to read more blogs in Patheos from Gospel for Asia.